How the function has evolved from scientific support to strategic driver and what it needs to look like in 2026.
Executive Summary (TL;DR)
The Problem: Most pharmaceutical companies have a Medical Affairs function. Fewer have a Medical Affairs strategy. Teams are reactive - responding to payer objections, patching publication gaps, and building KOL networks after launch when they should have been built during Phase 3. The result is a function that is scientifically credible but commercially invisible.
The Strategy: The Medical Affairs teams driving real commercial impact in 2026 are doing three things differently. They are building evidence plans around the questions payers will ask before those questions are asked. They are using AI to make MSL interactions more scientifically precise without losing the human relationship that makes those interactions valuable. And they are treating real-world evidence as a brand asset — not a compliance deliverable. The shift is from reactive support to proactive scientific strategy.
The Imperative: When Medical Affairs and commercial run on separate briefs, the same prescriber eventually hears two versions of the same brand story. The companies that have closed that gap - one scientific narrative, one commercial outcome are the ones whose payer negotiations and formulary access rates look different from everyone else's. Medical Affairs is ready to lead. The question is whether the organisation is built to let it.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1.
Role of Medical Affairs in Modern Healthcare
There is a version of Medical Affairs that most pharmaceutical companies built in the 1990s and early 2000s. A team that sat between R&D and commercial, answered HCP queries, organised advisory boards, and stayed carefully behind the regulatory firewall. It was useful. It was not strategic.
That version is being replaced. Quickly.
By 2026, Medical Affairs is no longer the function commercial teams pull in when they need scientific credibility for a message that was already written. In the pharmaceutical companies getting this right, it is the function that shapes evidence strategy before Phase 3 is complete, builds the KOL relationships that define how a therapy area thinks about a condition, and generates the real-world data that payers ask for before they will agree to reimburse. It is, in short, the function that determines whether a clinically strong asset becomes a commercially successful brand or not.
This is what medical affairs actually is in 2026, how it works, and what separates the teams doing it well from those still running the 1990s version.
Medical Affairs is the function within pharmaceutical, biotechnology, and medical device companies which is responsible for scientific communication, evidence generation, and stakeholder engagement. Medical affairs don’t have any promotional intent and exist to provide answers to questions that commercial teams can’t answer credibly as concrete research and evidence is required. Such credibility covers – now that we have this treatment, how do we ensure it reaches the patients who need it, is used correctly by the clinicians who prescribe it, and is valued appropriately by the payers who fund access to it? That question requires clinical credibility – which is precisely why Medical Affairs operates as a distinct function, separate from sales and marketing, with its own reporting line and its own scientific mandate.
“Medical Affairs is not the scientific conscience of the commercial team. It is the scientific engine of the brand.”
The visible outputs of Medical Affairs such as advisory board meetings, MSL field visits, congress symposia are the surface layer. The strategic value sits underneath them.
MSLs are the field-based face of the function. They are medically trained professionals – MDs, PharmDs, and PhDs who engage in peer-to-peer scientific exchange with healthcare professionals and Key Opinion Leaders. They do not promote products.Rather they focus on discussing clinical data and emerging evidence, capturing insights from clinical practice and building scientific relations that take years to develop. Such relationships can’t be replicated by some sales representative who keeps on hopping from one brand to another.
In 2026, the MSL role is being fundamentally reshaped by AI. The best MSLs are no longer simply carrying data to prescribers. They are arriving at every interaction having already synthesised what that specific clinician has published recently, what their digital discourse suggests they care about, and where the gaps in their clinical practice are. The relationship-building remains human. The preparation is increasingly machine-assisted and better for it.
Key Opinion Leaders are not just names on a speaker list. They are the clinicians whose published research, clinical trial participation, and peer conversations actively shape how a therapy area thinks – about a condition, its diagnosis, its treatment sequence, and the evidence that matters. Getting into that conversation early, with a genuine scientific mandate rather than a commercial one, is one of the highest-return activities in medical affairs. The word genuine is doing important work there. KOLs who feel used for brand endorsement disengage. Those given a real scientific role, shaping evidence plans, challenging trial design assumptions, contributing to publication strategy become the kind of long-term advocates that no amount of promotional spend can manufacture.
The word genuine is doing important work in that sentence. Advisory boards designed to validate decisions already made produce generic feedback and, over time, produce KOLs who attend for the fee rather than the science. The boards that produce intelligence that actually changes strategy are built around a specific question the medical affairs team genuinely needs answered and those experts know the difference.
Clinical trials are designed to answer whether a therapy works under controlled conditions. Payers, HTA bodies, and formulary committees increasingly want to know whether it works in actual clinical practice in the patients who present in a district hospital in Hyderabad or a community clinic in Manchester, not the carefully selected trial population.
Real-World Evidence generation i.e. observational studies, patient registries, claims data analytics is how Medical Affairs provides that answer. And in 2026, it is not just a payer requirement. Brands with robust post-marketing real-world evidence are harder to displace at formulary, more defensible against generic entry, and better positioned to demonstrate value under EU Joint Clinical Assessment requirements.
A clinical dataset that does not get published is a missed opportunity. A publication plan without strategic sequencing is a wasted one.Medical Affairs owns the publication strategy – not as an exercise in placing manuscripts, but as a multi-year plan that constructs the brand’s scientific evidence base milestone by milestone. Phase 3 readout, post-marketing surveillance, real-world studies, all such publications mark their territory in the sequence because of what it sets up next. The end result of such studies is building a coherent clinical narrative and not a collection of standalone papers that arrived when the data was ready.
Medical information teams handle the incoming flow of scientific queries from HCPs, patients, and internal teams – ensuring every response is accurate, non-promotional, and compliant. In 2026, the volume of queries has grown beyond what traditional call-centre models can manage at the quality and speed HCPs expect. AI-powered medical information systems built on verified scientific sources, with audit trails and adverse event detection are becoming the standard operating model for companies that want to stay ahead of that gap.
HEOR generates the economic and quality-of-life data that payers use to assess value. Budget impact models, cost-effectiveness analyses, patient-reported outcome studies – these are the evidence types that determine formulary access in value-based healthcare systems. Medical Affairs owns this evidence base and is responsible for translating it into arguments that resonate with the non-clinical financial decision-makers who control the access decision.
This is the question that generates the most confusion inside pharmaceutical companies and the most regulatory risk when it is answered badly.
The distinction matters because it is a legal and ethical one, not just an organisational preference. Medical Affairs communicates scientific information. Commercial teams promote products. The firewall between them exists to protect the integrity of scientific exchange – to ensure that when an MSL sits down with an oncologist to discuss a trial, the oncologist can trust that what they are hearing is evidence-based, not sales-driven.
Where companies get into trouble is when the firewall becomes permeable – when Medical Affairs is used as a credibility vehicle for commercial objectives, when KOL relationships are cultivated primarily to drive prescriptions rather than to advance scientific understanding, or when publication plans are sequenced around launch timelines rather than evidence gaps.
The best pharmaceutical companies treat the firewall not as a constraint but as an asset. An HCP who trusts your Medical Affairs team because they have never experienced anything promotional from them is an HCP who engages honestly – sharing their clinical concerns, their patient experiences, and their prescribing reality. That insight is worth more commercially than a sales interaction dressed in scientific clothing.
→ The firewall between Medical Affairs and commercial is not a barrier to effectiveness. It is the source of Medical Affairs' credibility - and credibility is the only currency that earns genuine expert relationships.
Medical Affairs is not evolving smoothly. It is being pulled in five directions simultaneously – each one raising the bar for what the function needs to deliver.
The traditional KOL management model – periodic check-ins, static CRM notes, relationships managed on institutional memory is no longer sufficient when the volume of scientific data MSLs are expected to synthesise, and the quality of insights their organisations expect, have both grown well beyond what human capacity alone can deliver.
AI is closing that gap without replacing the human element that makes MSL relationships valuable. MSLs using AI-assisted call preparation tools arrive knowing what that specific clinician has published recently, what their digital discourse suggests they care about, and what the clinical gaps in their practice are. The relationship is still human. The preparation is machine-assisted. The result is a conversation of considerably higher scientific quality than the one it replaced.
RWE has been a compliance exercise for most pharmaceutical companies – generated because payers asked for it, not because the commercial team wanted it. That framing is being replaced, and the companies making the shift early are benefiting from it at the negotiating table.
The pharmaceutical companies winning formulary negotiations in 2026 are the ones that arrived with post-marketing real-world evidence already assembled – not built in response to a payer request, but anticipated and integrated into the medical affairs plan from Phase 3. For brands approaching loss of exclusivity, that evidence is even more important. It is what generic competitors cannot replicate, and it is what keeps the branded product in preferred formulary position when the patent cliff arrives.
Clinicians who shape therapy area thinking in 2026 do so not only through publications and conference presentations, but through digital platforms like LinkedIn posts, X threads, podcast appearances, and online medical community discussions. Digital Opinion Leaders – clinicians whose digital discourse drives prescribing patterns in real time are often not the same people as the traditional KOL list.
Medical Affairs teams that are mapping only institutional KOLs and missing the DOL layer are engaging with an incomplete influence map. The function has had to develop social listening capabilities and DOL mapping tools to identify who is shaping clinical thinking digitally and adapt engagement strategies to reach both populations.
The European Union Joint Clinical Assessment process already underway for oncology and advanced therapy medicinal products – represents the most significant shift in payer evidence requirements the industry has faced in a generation. EU JCA demands comparative clinical effectiveness evidence that most companies are not currently building into their Phase 3 programmes.
According to IQVIA’s 2026 analysis, only one in three pharmaceutical companies feels well prepared for EU JCA requirements. The window for preparation is closing. Medical Affairs teams that are not already building their evidence generation plans around EU JCA will arrive at submission with evidence packages that do not answer the questions being asked.
Patient-centricity has been a stated value of the pharmaceutical industry for over a decade. Most companies mean it. Fewer have built the infrastructure to deliver it.
In 2026, the gap between aspiration and operation is closing not because of a cultural shift, but because payers, HTA bodies, and regulators are now formally demanding evidence of patient-reported outcomes, quality-of-life impact, and caregiver burden alongside clinical efficacy data. The companies that treated patient evidence as a box to tick are scrambling to produce it retrospectively. The ones that built it into their medical affairs plan from Phase 3 are arriving at submissions with it already assembled.
Medical Affairs is the function best positioned to capture this evidence through patient registries embedded in support programmes, PRO instruments built into engagement workflows, and direct patient community engagement. The teams doing this well are not running separate patient research programmes alongside their medical affairs plan. They are building patient evidence generation into the medical affairs infrastructure from launch planning.
Every function in the pharmaceutical industry is being told that AI will transform its work. Medical Affairs is the function where that transformation is actually happening – not in pilots or proof-of-concept projects, but in production deployments that are changing how MSLs prepare for calls, how medical information is delivered at scale, and how field insights are synthesised into strategy.
The distinction that matters is between generic AI tools and pharma-specific AI systems. General-purpose language models used without domain-specific grounding, audit trail requirements, or adverse event detection are not appropriate for pharmaceutical medical affairs. The responses are too unpredictable, the sources too unverifiable, and the compliance exposure too significant for a function that operates under the scrutiny that medical affairs does.
Pharma-specific AI for medical affairs is different in architecture, not just in application. It is built on verified scientific sources – PubMed, peer-reviewed journals, authorised internal databases. It carries mandatory audit trails. It detects adverse events in real time. It operates with security architecture that prevents query data from reaching public AI models. And it produces outputs that can pass MLR review without manual rewriting.
Beyond medical information, AI is being applied across the function – MSL call preparation, KOL identification and segmentation, literature monitoring, publication gap analysis, insight synthesis from field notes, and pre-screening of scientific content for compliance. Each application reduces administrative burden and raises the quality of strategic output. The question for Medical Affairs leaders in 2026 is not whether AI should be part of the function. It is which use cases to prioritise first, and how to build internal capability that does not create permanent external dependency.
Not every pharmaceutical company needs a fully staffed in-house Medical Affairs function for every asset, every market, and every stage of the product lifecycle. Medical affairs outsourcing exists because the capability requirements of the function are deep, expensive to build, and variable across a portfolio.
The cases where outsourcing works particularly well are predictable: companies entering new therapy areas without established KOL networks or scientific credibility; biotech firms launching their first commercial asset with lean teams; established pharma companies with lifecycle products that need sustained RWE generation and publication planning without the overhead of a dedicated team; and multinational launches where local medical affairs capability does not exist in all target markets.
What to look for in a partner goes beyond scientific depth in the therapy area – many agencies have that. The differentiators are the integration between scientific communications and commercial strategy, the quality of the KOL network that can be activated, the compliance infrastructure already in place, and whether the technology stack was built for pharma or adapted from tools designed for other industries.
The medical affairs outsourcing market is growing at approximately 11% CAGR, driven by increasing clinical trial volumes, rising R&D expenditure, and growing evidence complexity across markets.
Medical Affairs strategy is where the function either earns its place at the leadership table or stays operationally reactive. The difference is almost always a planning horizon problem. Teams that start building the evidence strategy, KOL network, and publication plan during Phase 3 arrive at launch with commercial-ready scientific infrastructure. Teams that start at approval are permanently catching up.
A medical affairs strategy that drives commercial impact has five components. An evidence generation plan built around the questions payers will ask – not the ones that were easiest to answer in the Phase 3 design. A KOL and DOL landscape map that distinguishes between institutional influence and digital influence, and builds engagement strategies for both. A publication plan sequenced as a coherent narrative rather than a collection of standalone manuscripts. A medical information infrastructure capable of handling HCP queries at the volume and speed the market requires with the compliance architecture that pharmaceutical medical information demands. And a measurement framework that reports outcome metrics, not just output metrics. Publications per year is an output. Formulary access rate and HCP knowledge shift are outcomes.
The teams that build these five components into one integrated plan, rather than managing them as separate workstreams are the ones whose medical affairs function looks strategic rather than reactive when leadership reviews the commercial plan.
Sales and marketing teams promote products. Medical Affairs communicates science. That distinction sounds simple until you are in a room where the line is being asked to move and understanding why it cannot is what separates companies that build genuine HCP trust from those that erode it. The firewall between the two functions is not a bureaucratic inconvenience. It is what makes an MSL conversation worth having for the clinician on the other side of it.
An MSL is the field-based scientific face of the Medical Affairs function - typically an MD, PharmD, or PhD - who engages with healthcare professionals and Key Opinion Leaders in genuine peer-to-peer scientific exchange. No promotional agenda, no sales target. They discuss clinical data, share emerging evidence, and listen to what is actually happening in clinical practice. In 2026, AI tools are increasingly supporting how MSLs prepare for those conversations. The conversation itself is still entirely human and that is the point.
AI is being applied across the medical affairs function - for MSL call preparation, KOL identification and segmentation, literature monitoring, publication gap analysis, insight synthesis from field notes, and AI-driven pre-screening of scientific content for MLR review. Medical information services are increasingly powered by RAG-based AI systems trained on verified scientific sources, with audit trails and adverse event detection. The key distinction is between pharma-specific AI built for compliance and generic tools adapted from other industries; only the former is appropriate for pharmaceutical medical affairs.
Medical affairs outsourcing is the engagement of an external partner to deliver some or all medical affairs capabilities including RWE study design, publication planning, KOL engagement, medical information services, CME programmes, and regulatory compliance. It is commonly used by companies entering new therapy areas, launching first commercial assets, or requiring medical affairs capability in markets where in-house teams do not yet exist.
In-house medical affairs makes sense for companies with large, stable portfolios in established therapy areas where sustained capability investment is justified. Outsourcing makes sense for first-in-class launches, market entry into new geographies, lifecycle products requiring targeted RWE or publication support, or any situation where the capability required is deep but the duration is finite. Many companies use a hybrid model - in-house strategic leadership with outsourced execution capabilities in specific areas.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
